Company intelligence / Profile preview
CureGene
Shanghai, Shanghai, Chinacuregene.com.cn ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
CureGene’s lead asset, CG‑0255, is a next-generation antiplatelet agent targeting the P2Y12 receptor. It has completed Phase 1 trials in the US and is in Phase 2 for acute coronary syndrome in China. The company also has preclinical programs targeting obesity, respiratory infections, and hepatitis B
- Therapeutic areas
- CardiovascularEndocrinologyInfectious Diseases
- Modalities
- Small moleculeOligonucleotideSmall interfering RNA (siRNA)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
not reported as of June 2025; no major pharma partnerships disclosed
Beyond the preview
Go deeper on CureGene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CureGene.